Risperdal Judge Warns J&J Over Introducing FDA Docs

Law360, Philadelphia (January 30, 2015, 6:05 PM EST) -- The Pennsylvania state judge overseeing a trial in which a Johnson & Johnson unit stands accused of failing to warn about the risks of abnormal breast growth in young boys from anti-psychotic drug Risperdal cautioned the company's lawyers against introducing certain U.S. Food and Drug Administration documents Friday.

As cross-examination of former FDA Commissioner David Kessler began, Philadelphia Court of Common Pleas Judge Ramy Djerassi told Weil Gotshal & Manges LLP attorney Diane Sullivan that she should be cautious when pushing Kessler on what the FDA thought of his opinions.

Kessler had spent several days testifying that Janssen Pharmaceuticals Inc. had...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!